Idera Announces Issuance of US Patent for Oligonucleotide Compositions Targeted to Toll-like Receptors
News Oct 05, 2007
Idera Pharmaceuticals, Inc. has announced the issuance of US patent 7,276,489 (the ‘489 patent) for novel oligonucleotide compositions. The claims of this patent, entitled “Modulation of Immunostimulatory Properties of Oligonucleotide-Based Compounds By Optimal Presentation of 5’ Ends,” cover oligonucleotide compositions in which two oligonucleotides are attached together through their 3’ ends and contain various synthetic immune stimulatory motifs.
These claims provide additional protection for the Company’s TLR9-targeted compounds, including its two lead product candidates, IMO-2055 and IMO-2125.
“We are pleased to have received the claims of the ‘489 patent for novel structures of oligonucleotide compositions,’” said Sudhir Agrawal, D. Phil., Chief Executive Officer and Chief Scientific Officer.
“The claims of the ‘489 patent and our previously issued patents (e.g. US7,262,286; US7,176,296; US7,115,579; US7,105,495) are the result of our chemistry-based approach in identifying TLR9-targeted compounds. We are using the technologies claimed in our patents and patent applications to design novel compounds for our internal programs and for partnered programs.”
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE